Drugs / NBL-020
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05877924 | Aug 2023 → Aug 2025 overdue | cancer | NovaRock Biotherapeutics, Ltd | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2023-02-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2022-12-22 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗
NBL-020 FOR THE TREATMENT OF ADV ANCED SOLID TUMORS OBTAINS CLINICAL TRIAL APPROV AL IN THE U.S. |
| 2022-12-21 | NovaRock Biotherapeutics, Ltd | Regulatory NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-020 novarockbio.com ↗
NovaRock Biotherapeutics Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for NBL-020, a tumor necrosis factor receptor 2 (TNFR2) antibody for the treatment of advanced solid tumors. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-02-16 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINIAL TRIAL APPROVAL IN CHINA irasia.com ↗ |
| 2022-12-22 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - NBL-020 FOR THE TREATMENT OF ADVANCED SOLID TUMORS OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S. irasia.com ↗ |
| 2022-12-21 | NovaRock Biotherapeutics, Ltd | NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-020 novarockbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NBL-020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05877924 ↗ |
| Route | Intravenous | “Q3W, i.v.” NCT05877924 ↗ |